Crizotinib safe, effective for ALK+ pediatric ALCL, IMTs

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • In children with advanced anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMTs), crizotinib (Xalkori) is safe and effective.
Why this matters
  • Advanced ALCL and IMTs have a poor prognosis.
Study design
  • In this phase 2 Children's Oncology Group trial, safety and efficacy of crizotinib were studied at different doses in 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT.
  • Response was defined by a positive response for a minimum of 2 consecutive imaging studies at least 4 wk apart.
  • Funding: National Cancer Institute, Pfizer, and Cookies for Kids Cancer Foundation.
Key results
  • 83% of patients with ALCL who received a dose of 165 mg/m2 responded and 90% of patients who received a dose of 280 mg/m2 responded.
  • Complete response was seen in 83% of the 165 mg/m2 group and 80% of the 280 mg/m2 group of patients with ALCL.
  • 86% of patients with IMT responded (doses of 100, 165, and 280 mg/m2).
  • A complete response was seen in 36% of patients with IMT.
  • The most frequent adverse event was a lowering of neutrophil count in 33%-70% patients of the ALCL group and 43% patients of IMT group.
  • Small sample sizes.